Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: This session will review key developments in IP law and their impact on patent strategy with a focus on precision medicine and immuno-oncology. The session will provide background and updates on patent eligibility (section 101), tradeoffs between eligibility and the ability to effectively sue infringers. In addition, discuss legal developments that impact patent strategy for antibody or TCR-based products.
Session Chair Profile
Ph.D., Partner, Morrison & Foerster LLP
Biography
Dr. Polizzi is a Partner at Morrison & Foerster, where she helps emerging and established companies through the challenging process of obtaining patents, providing effective portfolio counseling and management. She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas, including personalized medicine, cancer and cancer immunotherapy, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular disease, metabolic disorders, and neurodegenerative diseases such as Alzheimer’s Diseases. She also works with small and large molecule therapies, drug delivery and formulation technologies, cell-based therapies, tumor microenvironment, microfluidics and genomic screening technologies. Her practice also includes due diligence evaluation and counseling in the context of venture investment assessments, as well as in connection with public and private financings, spin-offs, partnerships, and mergers and acquisitions. Dr. Polizzi is recognized as a leader in intellectual property law, including as a top intellectual property attorney in California for almost 10 years running, and is an inductee of the Legal Media Group Life Sciences Hall of Fame.
Speaker Profile
Ph.D., J.D, Partner, Fenwick & West LLP
Biography
Kevin Kabler, Ph.D., provides strategic patent counseling and due diligence to clients at all stages of the business cycle in the life sciences industry. He analyzes and evaluates third-party patents for risk reduction from assertions as well as investment purposes. He also analyzes patent portfolios for assertion and enforcement purposes against third parties. Kevin has extensive experience in developing and managing patent portfolios for companies and institutions in the life sciences industry, including preparation and prosecution of domestic and international patent applications.
